NATIONAL INSTITUTES OF HEALTH
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
- Conditions
- Myelodysplastic Syndrome
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow Biopsy
- First Posted Date
- 2024-08-29
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 54
- Registration Number
- NCT06577441
- Locations
- 🇺🇸
Kootenai Health - Coeur d'Alene, Coeur d'Alene, Idaho, United States
🇺🇸Kootenai Clinic Cancer Services - Post Falls, Post Falls, Idaho, United States
🇺🇸Kootenai Clinic Cancer Services - Sandpoint, Sandpoint, Idaho, United States
Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer
- Conditions
- Recurrent Head and Neck Cutaneous Squamous Cell CarcinomaRecurrent Skin Squamous Cell CarcinomaResectable Head and Neck Cutaneous Squamous Cell CarcinomaResectable Skin Squamous Cell CarcinomaStage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed TomographyRadiation: Image Guided Radiation TherapyRadiation: Intensity-Modulated Radiation TherapyProcedure: Magnetic Resonance ImagingProcedure: Positron Emission TomographyOther: Questionnaire AdministrationProcedure: Surgical Procedure
- First Posted Date
- 2024-08-23
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 420
- Registration Number
- NCT06568172
- Locations
- 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸Tower Cancer Research Foundation, Beverly Hills, California, United States
🇺🇸UC San Diego Health System - Encinitas, Encinitas, California, United States
An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous Polyposis
- Conditions
- Familial Adenomatous Polyposis
- Interventions
- Procedure: Biopsy ProcedureProcedure: Biospecimen CollectionDrug: EP2/EP4 Antagonist TPST-1495Procedure: EsophagogastroduodenoscopyProcedure: Gastrointestinal EndoscopyOther: Questionnaire Administration
- First Posted Date
- 2024-08-16
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 38
- Registration Number
- NCT06557733
- Locations
- 🇵🇷
University of Puerto Rico, San Juan, Puerto Rico
🇺🇸Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
🇺🇸Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Sacituzumab Govitecan Alone in the Treatment of Advanced Urothelial Cancer
- Conditions
- Locally Advanced Urothelial CarcinomaMetastatic Urothelial Carcinoma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Magnetic Resonance ImagingOther: Questionnaire Administration
- First Posted Date
- 2024-07-29
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 384
- Registration Number
- NCT06524544
Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Buccal Swab
- First Posted Date
- 2024-07-23
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 45
- Registration Number
- NCT06514261
- Locations
- 🇺🇸
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
🇺🇸UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸University of Cincinnati Cancer Center-UC Medical Center, Cincinnati, Ohio, United States
A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using Pupillometry in Participants With Neurofibromatosis Type 1 (NF1)
- Conditions
- Neurofibromatosis Type 1
- Interventions
- Device: AlgometRx Nociometer
- First Posted Date
- 2024-07-18
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 70
- Registration Number
- NCT06507748
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
- Conditions
- Bladder CancerPancreatic Ductal AdenocarcinomaCholangiocarcinomaGastric CancerHepatocellular CarcinomaPheochromocytomaOvarian Cancer
- Interventions
- Drug: [18F]FDG
- First Posted Date
- 2024-07-16
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 320
- Registration Number
- NCT06503146
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial
- Conditions
- Human Papillomavirus InfectionCervical Carcinoma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Cervical BiopsyProcedure: ColposcopyOther: Electronic Health Record ReviewProcedure: Endocervical CurettageProcedure: ExcisionProcedure: HPV Self-CollectionProcedure: Human Papillomavirus TestOther: Questionnaire AdministrationOther: Survey Administration
- First Posted Date
- 2024-07-12
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 520
- Registration Number
- NCT06498661
- Locations
- 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸UCSF Medical Center-Parnassus, San Francisco, California, United States
🇺🇸Yale University, New Haven, Connecticut, United States
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
- Conditions
- Advanced Dedifferentiated LiposarcomaAdvanced LeiomyosarcomaAdvanced Soft Tissue SarcomaMetastatic Dedifferentiated LiposarcomaMetastatic LeiomyosarcomaMetastatic Soft Tissue SarcomaStage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
- Interventions
- Procedure: Biopsy ProcedureProcedure: Biospecimen CollectionOther: Fluorothymidine F-18Procedure: Positron Emission Tomography
- First Posted Date
- 2024-07-12
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 74
- Registration Number
- NCT06498648
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Conditions
- Lung Non-Small Cell CarcinomaStage IIIB Lung Cancer AJCC v8Stage II Lung Cancer AJCC v8Stage IIIA Lung Cancer AJCC v8
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed TomographyOther: Patient ObservationOther: Questionnaire Administration
- First Posted Date
- 2024-07-12
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 306
- Registration Number
- NCT06498635
- Locations
- 🇺🇸
NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro, Jonesboro, Arkansas, United States
🇺🇸Hartford Hospital, Hartford, Connecticut, United States
🇺🇸Midstate Medical Center, Meriden, Connecticut, United States